Recent investigations conducted in our laboratory have demonstrated that in metabolic dysfunction associated fatty liver disease, KIF13B interacts with AMPKα1 to inhibit hepatic de novo lipogenesis and improve FA oxidation, thereby preventing the development of fatty liver disease [15], indicating that KIF13B plays an important role in lipid metabolism homeostasis. Here, PRKAA1 is linked to fatty liver disease.